Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58
De Sanjose, Silvia (PATH, Scale-Up Project Director, Sexual and Reproductive Health Global Program)
Serrano, Beatriz (Centro de Investigación Biomédica en Red de Cáncer)
Tous, Sara (Centro de Investigación Biomédica en Red de Cáncer)
Alejo, Maria (Hospital General de l'Hospitalet)
Lloveras, Belén (Hospital del Mar (Barcelona, Catalunya))
Quirós, Beatriz (Centro de Investigación Biomédica en Red de Cáncer)
Clavero, Omar (Centro de Investigación Biomédica en Red de Cáncer)
Vidal, August (Hospital Universitari de Bellvitge)
Ferrandiz-Pulido, Carla (Hospital Universitari Vall d'Hebron)
Pavón, Miquel Ángel (Centro de Investigación Biomédica en Red de Cáncer)
Holzinger, Dana (German Cancer Research Center (DKFZ))
Halec, Gordana (David Geffen School of Medicine at UCLA.Obstetrics and Gynecology Department)
Tommasino, Massimo (International Agency for Research on Cancer Infections)
Quint, Wim (DDL Diagnostic Laboratory)
Pawlita, Michael (German Cancer Research Center (DKFZ))
Muñoz, Nubia (National Cancer Institute of Colombia)
Bosch José, Francesc Xavier 1947- (Centro de Investigación Biomédica en Red de Cáncer)
Alemany, Laia (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública)
Universitat Autònoma de Barcelona

Data:	2019
Resum:	Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vaccination programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA-positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16 INK4a immunohistochemistry. For cervical cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16 INK4a biomarkers. The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22. 8% of vulvar, 24. 5% of penile, 60. 7% of vaginal, 79. 0% of anal cancers, 21. 3% of oropharyngeal, 4. 0% of oral cavity, and 2. 7% of laryngeal cancer cases. Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.
Ajuts:	Instituto de Salud Carlos III PS09/00253 Instituto de Salud Carlos III PI030240 Instituto de Salud Carlos III PI061246 Instituto de Salud Carlos III PI081535 Instituto de Salud Carlos III PI1102096 Instituto de Salud Carlos III PI1102104 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR1085 European Commission 282562
Nota:	Altres ajuts: FICMAC/017-2014
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	JNCI Cancer Spectrum, Vol. 2 (january 2019) , ISSN 2515-5091

DOI: 10.1093/jncics/pky045
PMID: 31360870

11 p, 2.9 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats